Aktieanalys

Hansa Biopharma: Improved use of IDEFIRIX - Redeye

Redeye Publicerad: 17 Oct 09:20

Hansa delivers a healthy increase in patients using IDEFIRIX. Discounts and rebates offset this, and the net sales align with expectations. We welcome ongoing adjustments for discounts and rebates, which reduces the need for annual larger “true-ups”. The impact on the valuation and the outlook is likely related to the outlook for discounts and rebates, which could stabilise at a lower level going forward. In Q3, the total level of these provisions was approximately 43%. When adjusting for provisions actually relating to Q3, net sales would have been a very impressive SEK 64.6m and rebates of 7%

Länk till analysen i sin helhet: https://www.redeye.se/research/1043867/hansa-biopharma-improved-use-of-idefirix?utm_source=finwire&utm_medium=RSS

Nyheter om Hansa Biopharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!